Curated News
By: NewsRamp Editorial Staff
July 22, 2025
Calidi Biotherapeutics to Showcase RedTail(TM) Platform in Investor Webinar
TLDR
- Calidi Biotherapeutics' investor webinar on July 24, 2025, offers a strategic advantage by detailing their RedTail(TM) platform and CLD-401's tumor elimination potential.
- Calidi Biotherapeutics will explain the RedTail(TM) platform's mechanism for systemic viral therapy delivery to treat metastatic tumors during their July 24 webinar.
- Calidi Biotherapeutics' innovative therapies aim to enhance cancer treatment efficacy and patient safety, promising a brighter future for oncology care.
- Discover how Calidi Biotherapeutics' RedTail(TM) platform and CLD-401 candidate are revolutionizing cancer treatment with tumor elimination and immune memory activation.
Impact - Why it Matters
This news is significant as it highlights Calidi Biotherapeutics' progress in developing innovative cancer treatments that could offer new hope to patients with metastatic tumors. The RedTail(TM) platform's ability to evade immune detection and target tumors systemically represents a potential paradigm shift in oncology therapy. For investors and the medical community, Calidi's advancements underscore the growing importance of genetic medicine in treating complex diseases, marking a critical step forward in the quest for more effective and safer cancer treatments.
Summary
Calidi Biotherapeutics (NYSE American: CLDI), a pioneering clinical-stage biotech firm, is set to host an investor webinar on July 24, 2025, to discuss its innovative RedTail(TM) platform. This platform represents a breakthrough in targeted genetic medicine therapies, specifically designed to treat metastatic tumors by avoiding immune detection. Under the leadership of CEO Eric Poma, Ph.D., the webinar will highlight preclinical data demonstrating the efficacy of lead candidate CLD-401, which has shown promising results in tumor elimination and immune memory activation. Calidi is on the path to filing an Investigational New Drug (IND) application and is actively seeking strategic pharmaceutical partnerships to facilitate the commercialization of its groundbreaking therapies. The event will conclude with a Q&A session, offering attendees a deeper insight into Calidi's vision and progress.
For those interested in learning more about Calidi Biotherapeutics and its revolutionary approach to cancer treatment, additional information can be found on their website at www.calidibio.com. The company's commitment to developing off-the-shelf, universal cell-based delivery platforms and enveloped virotherapies positions it as a leader in the fight against high-grade gliomas and solid tumors, potentially transforming the landscape of oncology treatment.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Calidi Biotherapeutics to Showcase RedTail(TM) Platform in Investor Webinar
